Table 3 Unadjusted and adjusted risk difference between recombinant thrombomodulin use and outcomes
Outcomes | Cluster dA | p value | Cluster dB | p value | Cluster dC | p value | Cluster dD | p value |
|---|---|---|---|---|---|---|---|---|
Associations in the derivation cohorts, risk difference, % (95%CI) | ||||||||
Unadjusted association (vs. non rhTM use) | ||||||||
 28-Day death | − 10.8 (− 21.5 to − 0.1) | 0.047 | 3.5 (− 4.6 to 11.5) | 0.40 | − 1.9 (− 6.9 to 3.2) | 0.47 | 2.2 (− 2.8 to 7.1) | 0.39 |
 In-hospital death | − 10.9 (− 20.8 to − 1.1) | 0.03 | 1.6 (− 7.2 to 10.3) | 0.73 | − 8.0 (− 13.8 to − 2.3) | 0.01 | 0.8 (− 5.2 to 6.8) | 0.78 |
Adjusted association (vs. non rhTM use) | ||||||||
 28-Day death | − 17.8 (− 28.7 to − 6.9) | 0.001 | 0.7 (− 7.1 to 8.6) | 0.85 | − 3.1 (− 8.3 to 2.1) | 0.24 | − 0.7 (− 4.5 to 6.0) | 0.79 |
 In-hospital death | − 17.7 (− 27.6 to − 7.8) | < 0.001 | 0.2 (− 7.9 to 8.3) | 0.97 | − 10.2 (− 15.9 to − 4.6) | < 0.001 | − 1.3 (− 7.6 to 4.9) | 0.67 |
| Â | Cluster vA | p value | Cluster vB | p value | Cluster vC | p value | Cluster vD | p value |
|---|---|---|---|---|---|---|---|---|
Associations in the validation cohorts, risk difference, % (95%CI) | ||||||||
Unadjusted association (vs. non-rhTM use) | ||||||||
 28-Day death | − 15.0 (− 32.2 to 2.2) | 0.09 | 3.2 (− 12.5 to 18.9) | 0.69 | 4.4 (− 5 to 13.8) | 0.36 | 7.1 (− 2.4 to 16.6) | 0.14 |
 In-hospital death | − 22.2 (− 39.6 to − 4.9) | 0.01 | 8.8 (− 7.3 to 24.8) | 0.29 | 5.7 (− 4.9 to 16.2) | 0.3 | 14.2 (3.8 to 24.7) | 0.008 |
Adjusted association (vs. non rhTM use) | ||||||||
 28-Day death | − 24.9 (− 49.1 to − 0.7) | 0.04 | − 5.7 (− 29.9 to 18.5) | 0.64 | 1.4 (− 12.8 to 15.7) | 0.84 | − 6.7 (− 19.4 to 6.0) | 0.3 |
 In-hospital death | − 30.9 (− 55.3 to − 6.6) | 0.01 | − 3.7(− 27.9 to 20.5) | 0.77 | − 0.5 (− 16.1 to 15.1) | 0.95 | 0.7 (− 13.0 to 14.5) | 0.92 |